Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Tislelizumab for Resectable Small Cell Lung Cancer in Stage IIB-IIIB: A Phase 2 Trial

NCT07109401 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07109401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07109401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Tislelizumab for Resectable Small Cell Lung Cancer in Stage IIB-IIIB: A Phase 2 Trial
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
March 1, 2025
Completion date
December 31, 2028
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

limited stage lung small cell carcinoma, perioperative immunotherapy, resectable small cell lung cancer